Virtual Library
Start Your Search
J. Watanabe
Author of
-
+
Poster Session (ID 8)
- Event: ACLC 2018
- Type: Poster Session
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 11/07/2018, 00:00 - 00:00, Poster Hall
-
+
P050 - Long-Term Survival of Stage IIIA-N2 NSCLC Patients with Interstitial Lung Diseases (ID 210)
00:00 - 00:00 | Author(s): J. Watanabe
- Abstract
Background:
Interstitial lung diseases (ILD) frequently occur in patients with lung cancer. The optimal treatment strategy for non-small-cell lung cancer (NSCLC) patients with ILD remains unclear. We reviewed the efficacy and safety of surgery, chemotherapy, and radiotherapy.
Method:
We analyzed the medical records of patients with clinical stage IIIA-N2 NSCLC with ILD who were treated at our hospital between 2001 and 2016.
Results:
505 patients with clinical stage IIIA-N2 NSCLC were included. Of these patients with ILD, treatments included surgical resection (S) in 14 patients, chemoradiotherapy (CRT) in 7 patients, palliative chemotherapy (C) in 7 patients and palliative radiotherapy in one patient.The median follow-up period was 38 months. The patients' characteristics were as follows S/CRT/C: male, 26/6/7 patients; median age (range), 69 (58-82)/69 (60-75)/69 (35-82) years. Of the S, pathological stage IA/IIA/IIB/IIIA/IIIB, 1/1/2/9/1 patients. The median progression-free survival times were 9.5 months (95% CI: 5.3-45.3 months) in S, 45.9 months (95% CI: 7.2 months- not reached [NR]) in CRT, and 5.0 months (95% CI: 0.5-10.5 months) in C. The median overall survival time were 33.3 months (95% CI: 9.8 months-NR) in S, 45.9 months (95% CI: 8.3 months-NR) in CRT, and 9.9 months (95% CI: 1.6-42.4 months) in C. One patient died within 1 month of surgical resection. Acute exacerbations of ILD (AE-ILD) were noted in 14 % of the patients; 3 patients after surgery and 1 patient after chemoradiotherapy.
Conclusion:
The surgery and chemoradiotherapy can be considered as a treatment option for selected patients with IIIA-N2 NSCLC with ILD, with careful management after sufficient evaluation of the risks and the benefits.